News

The late-breaking data were presented by Nicholas Butowski, M.D., a principal investigator on the trial and Professor of Neurological Surgery at the University of California San Francisco Weill

Remsima SC is claimed to be the world’s first subcutaneous formulation of infliximab. The EC approval was based on clinical evidence, including results from a study that demonstrated

The late-stage trial called IMbrave150 evaluated the Tecentriq, Avastin combination in comparison with sorafenib in 501 patients with unresectable HCC, who did not receive prior systemic therapy. Data

Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD. The designation of psilocybin as a Breakthrough Therapy for MDD acknowledges

“We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suffering from this complex and unpredictable disease,” said John Orloff, M.D.,

As per the terms of the deal, Novartis has offered to buy the US-based biopharmaceutical company for $85.00 per share in cash. Headquartered in Parsippany, New Jersey, The

Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop up to five engineered

Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells. N6LS is an antiviral bNAb that works by

Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity. The FDA approval was based on data from